Education
About Us
Working with TipRanks
Follow Us
Cronos Australia Ltd. (AU:VIT)
ASX:VIT
VIT Stock Chart & Stats
AU$0.06
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.06
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.08
Previous CloseN/A
Volume1.00K
Average Volume (3M)228.84K
Market Cap
AU$27.84M
Enterprise ValueAU$38.41M
Total Cash (Recent Filing)AU$6.10M
Total Debt (Recent Filing)AU$17.34M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.28%
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding662,741,800
10 Day Avg. Volume238,134
30 Day Avg. Volume228,844
Financial Highlights & Ratios
PEG Ratio-1.01
Price to Book (P/B)0.78
Price to Sales (P/S)0.30
P/FCF Ratio14.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA low debt-to-equity ratio and a high equity ratio indicate conservative leverage and a strong capital base. This durable financial structure gives the company flexibility to fund R&D, weather industry downturns, and pursue strategic initiatives without overreliance on external financing.
Gross Margin StabilityA stable gross margin around 27% points to effective cost control or pricing resilience in the specialty/generic drug business. Durable gross margins support long-term operating leverage, enabling the company to maintain profitability even if revenue growth is slow.
High FCF Conversion RatioConverting nearly all reported net income into free cash flow indicates underlying cash-realization ability. Over the medium term this supports dividend payouts, working capital needs and reinvestment, reducing reliance on financing despite volatile FCF growth.
Bears Say
Weak Cash-Flow TrendsA dramatic decline in free cash flow growth and very low operating cash flow relative to net income signal volatile, stressed cash generation. Persistently weak cash inflows limit reinvestment, increase refinancing risk and pressure the sustainability of dividends or expansion plans.
Declining RevenueRecent revenue contraction undermines scale and can erode competitive position in specialty/generic markets. Sustained or repeated declines reduce pricing leverage, make fixed costs more burdensome and constrain long-term margin expansion and R&D funding.
Low Profitability & EPS PressureA very modest net margin and sharp EPS decline indicate weak bottom-line performance and earnings volatility. Over months, low profitability limits internal cash for growth, weakens investor returns and signals operational or demand challenges needing structural fixes.
Cronos Australia Ltd. News
VIT FAQ
What was Cronos Australia Ltd.’s price range in the past 12 months?
Cronos Australia Ltd. lowest share price was AU$0.04 and its highest was AU$0.08 in the past 12 months.
What is Cronos Australia Ltd.’s market cap?
Cronos Australia Ltd.’s market cap is AU$27.84M.
When is Cronos Australia Ltd.’s upcoming earnings report date?
Cronos Australia Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 179 days.
How were Cronos Australia Ltd.’s earnings last quarter?
Cronos Australia Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.001.
Is Cronos Australia Ltd. overvalued?
According to Wall Street analysts Cronos Australia Ltd.’s price is currently Overvalued.
Does Cronos Australia Ltd. pay dividends?
Cronos Australia Ltd. pays a Annually dividend of AU$0.002 which represents an annual dividend yield of 3.28%. See more information on Cronos Australia Ltd. dividends here
What is Cronos Australia Ltd.’s EPS estimate?
Cronos Australia Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cronos Australia Ltd. have?
Cronos Australia Ltd. has 662,741,800 shares outstanding.
What happened to Cronos Australia Ltd.’s price movement after its last earnings report?
Cronos Australia Ltd. reported an EPS of -AU$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.167%.
Which hedge fund is a major shareholder of Cronos Australia Ltd.?
Currently, no hedge funds are holding shares in AU:VIT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cronos Australia Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.51%
12-Months-Change
Fundamentals
Return on Equity
7.64%
Trailing 12-Months
Asset Growth
5.91%
Trailing 12-Months
Company Description
Cronos Australia Ltd.
Vitura Health Limited engages in the sale and distribution of medicinal cannabis products in Australia and Asia. Its brands include CanView, Burleigh Heads Cannabis, CDA Clinics, Cannadoc, and Adaya. The company was formerly known as Cronos Australia Limited and changed its name to Vitura Health Limited in February 2023. The company was incorporated in 2018 and is based in South Yarra, Australia.
Technical Analysis
Elixinol Wellness
―
Cann Group
―
Epsilon Healthcare Limited
―
Little Green Pharma Ltd.
―
―
Options Prices
Currently, No data available
---